Arsénio M. Fialho is associate professor in the Bioengineering Department of Instituto Superior Técnico and principal investigator in the Biological Science Research Group, Institute for Bioengineering and Biosciences, at the University of Lisbon, Lisbon, Portugal. His teaching and research interests are in molecular and cellular biology. His research focuses on the study of bacterial proteins/peptides as novel drug candidates for cancer therapy and aims to elucidate the cellular and molecular effects of treating cancer cell models with the protein azurin and its fragment, a cell-penetrating peptide of 28 amino acids known as p28. The p28 peptide successfully completed two phase I clinical trials in the United States. Prof. Fialho is also interested in the development of nanocarriers for anticancer drugs and study of trimeric autotransporter adhesins as novel and key virulence determinants in members of the Burkholderia cepacia complex. He serves as an expert for several national and international funding agencies and organizations. He has authored of 75 articles in peer-reviewed scientific journals, 2 books, and 13 book chapters and holds 8 US patents.
Ananda M. Chakrabarty is a distinguished university professor of microbiology and immunology at the University of Illinois College of Medicine and advises senior officials in the United States and abroad on the policies relating to biotechnology and associated technology transfer. As a consultant to the United Nations, he was on the advisory committee that resulted in the creation of the International Center for Genetic Engineering and Biotechnology in Trieste, Italy. In 1980, Dr. Chakrabarty's genetically modified Pseudomonas bacteria became the first genetically engineered organism to gain a patent, as a result of the Supreme Court decision in Diamond v. Chakrabarty. He has continued to undertake pioneering biotechnology research into the therapeutic potential for protein products of bacteria, both at the University of Illinois at Chicago and on behalf of CDG Therapeutics (USA) and Amrita Therapeutics (India), two biotechnology start-ups engaged in clinical cancer research. Dr. Chakrabarty has more than 280 research publications to his credit and has received many notable international awards for his contributions to biotechnology.
Bifidobacterium as a Delivery System of Functional Gene for Cancer Gene Therapy
Chao Han, Yu-qing Dai, Zi-chun Hua, Geng-Feng Fu, Yan Yin, Bi Hu, and Gen-xing Xu
Therapy with Oncolytic Clostridium novyi-NT: From Mice to Men
Shibin Zhou
Genetic Engineering of Clostridial Strains for Cancer Therapy
Maria Zygouropoulou, Aleksandra Kubiak, Adam V. Patterson, and Nigel P. Minton
Bacteria-Derived Alternatives to Live Mycobacterium bovis Bacillus Calmette-Guerin for Non-Muscle Invasive Bladder Cancer Treatment
Esther Julián and Estela Noguera-Ortega
Genetically Modified Salmonella as Cancer Therapeutics: Mechanisms, Advances and Challenges
Xiaoxin Zhang and Zi-Chun Hua
Genetically Engineered Oncolytic Salmonella typhimurium
Jin Hai Zheng and Jung-Joon Min
Engineering E. coli to Combat Cancer
Carlos Piñero-Lambea, David Ruano-Gallego, Gustavo Bodelón, Beatriz Álvarez, and Luis Ángel Fernández
Live P. aeruginosa as Cancer Vaccine Vector
Y. Wang, B. Polack, and B. Toussaint
The Anticancer Potential of the Bacterial Protein Azurin and Its Derived Peptide P28
Ana Rita Garizo, Nuno Bernardes, Ananda M. Chakrabarty, and Arsénio M. Fialho
Bacteriocins: From Antimicrobial to Potencial Anticancer Agents
Lígia Coelho, Nuno Bernardes, and Arsénio M. Fialho
Bacteriocins as Anticancer Peptides? A Biophysical Approach
Filipa Dias de Oliveira, Miguel A. R. B. Castanho, and Diana Gaspar
Where Cancer and Bacteria Meet
Alexandra Merlos, Ricardo Perez-Tomás, José López-López, and Miguel Viñas